Becton, Dickinson and Company BDX, also known as BD, recently announced the submission of a pre-market approval (PMA) to the FDA for an expanded version of its BD Onclarity HPV (human papilloma virus) Assay.
Following the announcement, shares of the Zacks Rank #3 (Hold) company rose 2.5% to $248.30 at close.
Per management, the PMA submission is a significant step by BD toward enhancing women’s health and cancer portfolio.
More on BD Onclarity HPV Assay
The BD Onclarity HPV Assay detects and identifies 14 high-risk HPVs for cervical cancer screening purposes. The assay can be used with BD SurePath Collection Vial and the Hologic PreservCyt Solution for cervical cancer prevention.
The BD Onclarity HPV Assay is the only FDA-approved assay to individually identify and report different HPV genotypes associated with cervical cancer.
Notably, a PMA will provide laboratories and clinicians worldwide with comprehensive cervical cancer screening solutions.
An article by Cancer.Net predicts that an estimated 13,170 women in the United States are likely to be diagnosed with the disease in 2019.
BD and Women’s Health
Through the development of novel molecular oncology products, BD offers next-generation solutions in the field of cervical, ovarian and breast cancer.
The products include BD Totalys MultiProcessor, BD FocalPoint GS Imaging System and BD ProEx Reagent.
Focus on women’s health has increased in recent years and has considerably ramped up investments. From AI in women healthcare, cancer drugs to In Vitro Fertilization, the women’s health market is gearing up for a wave of innovation.
For instance, tech giant Intel INTC has partnered with privately-held MobileODT to develop an algorithm which identifies a woman’s cervix type based on images.
Per Global Market Insights, the global women’s health devices market is set to surpass $42.5 billion by 2025.
In a year’s time, shares of BD have rallied 3.3% against the industry’s 5.8% decline.
Some better-ranked stocks in the broader medical sector are DexCom DXCM and CONMED Corporation CNMD. While DexCom sports a Zacks Rank #1 (Strong Buy), CONMED carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
DexCom’s fourth-quarter earnings growth is projected at 29.6%.
CONMED’s long-term earnings growth rate is expected to be 17%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
CONMED Corporation (CNMD) : Free Stock Analysis Report
Intel Corporation (INTC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research